Vancouver-based leader in cancer detection technology Verisante Technology Inc., has been honoured by Frost & Sullivan with the 2014 North American Technology Innovation Leadership of the Year Award.
The designation recognized the firm’s In Vivo Cancer Detection product, Verisante Aura, a device for the detection of skin cancer.
“Verisante is pleased to accept the recognition of Aura as an innovative and disruptive technology that can make a positive impact on healthcare outcomes for skin cancer patients,” says Thomas Braun, president and CEO. “As more Aura units are placed in clinics we believe this innovative technology can become part of the standard of care for assisting doctors in monitoring and diagnosing skin cancer.”
Frost & Sullivan follows a 10-step process to evaluate candidates and assess their fit with its best-practice criteria. Frost & Sullivan’s global network of consultants and analysts are asked to monitor, target, analyze and screen creative practices within their regions and to confer with their industry peers. An independent board of advisors considers the findings in order to choose the company that excels in its industry above all others in customer value leadership. Based on its analysis of the in vivo cancer detection market, Frost & Sullivan recognized Verisante as the leader for its commitment to innovation and technology excellence.
“Aura has a unique competitive advantage in the marketplace as it is capable of providing almost instantaneous information about the biochemical nature of a skin lesion,” notes Frost & Sullivan industry analyst, Darshana De. “This advantage, and the potential for the same technology to be used for the detection of lung, colon and cervical cancer, differentiates Verisante as a leader in technology innovation.”